ZMAT3

Across TCGA pan-cancer cohorts, ZMAT3 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ZMAT3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ZMAT3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZMAT3 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

THCA, KIRP, and LIHC are the cancer types where ZMAT3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZMAT3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	III,IV	+1.546	<.001	10	view →
KIRP	Female	II,III,IV	+2.068	<.001	9	view →
LIHC	All	III,IV	+0.919	<.001	7	view →
HNSC	All	III,IV	+0.653	.005	6	view →
KICH	All	All	−0.944	<.001	5	view →
CHOL	All	All	+1.202	.005	4	view →
BRCA	Female	All	−0.370	<.001	4	view →
UCEC	All	All	−0.937	<.001	2	view →
PRAD	All	All	−0.383	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

ZMAT3–THCA

Open the THCA breakdown →